Melanie M. Sinanian

Melanie M. Sinanian

Auto-generated profile, based on publicly available information

Melanie M. Sinanian

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
MSMelanie M. Sinanian
Melanie M. Sinanian
ECEesha Chakraborty
Eesha Chakraborty
AEAhmed Elshazly
Ahmed Elshazly
SAShady Azzam
Shady Azzam
NNNada Nassif
Nada Nassif
David GewirtzDavid Gewirtz
David Gewirtz
Antibody-drug conjugates (ADCs) are an emerging class of cancer therapeutics comprised of a tumor-targeting antibody linked to a cytotoxic payload. Sacituzumab govitecan (SG or IMMU-132) is comprised of a trophoblast cell-surface antigen 2 (TROP-2)-directed antibody linked to the topoisomerase 1 inhibitor, SN-38. SG was designed to exploit the overexpression of TROP-2, observed in a variety of different epithelial cancers, to enhance tumor-selective cytotoxicity while minimizing damage to normal tissues. SG is approved for pretreated metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive human epidermal growth factor receptor 2 (HER2) negative breast cancer patients. While SG has shown significant clinical benefit, the objective response rate (ORR) observed with SG in pretreated mTNBC patients in the Phase I/II basket study was 33.3%, indicating a heterogeneous response profile to SG. This article explores the potential influence of autophagy, senescence, and the patient’s immune system on the treatment response.

21 July 2026 in Molecular Pharmacology
Verified
Journal Article
Closed access
ECEesha Chakraborty
Eesha Chakraborty
MSMelanie Sinanian
Melanie Sinanian
ARAfshan Rahman
Afshan Rahman
David GewirtzDavid Gewirtz
David Gewirtz